128117-22-6

Usage

Uses

Used in Organic Synthesis:
Benzyl 3-hydroxyazetidine-1-carboxylate is utilized as a building block in organic synthesis for its ability to facilitate the creation of complex organic molecules. The benzyl group provides a stable and versatile platform for further chemical modifications, enhancing the compound's utility in the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Benzyl 3-hydroxyazetidine-1-carboxylate is employed as a key intermediate in the development of potential drug candidates. Its unique structure and functional groups make it a promising starting material for the design and synthesis of new pharmaceuticals with potential therapeutic applications.
Used in the Development of Biologically Active Compounds:
Due to its 3-hydroxy and carboxylate functional groups, Benzyl 3-hydroxyazetidine-1-carboxylate is used as a precursor in the synthesis of biologically active compounds. These functional groups can be exploited to create molecules with specific interactions and binding affinities, which are crucial for the development of effective drugs and other bioactive substances.
Overall, Benzyl 3-hydroxyazetidine-1-carboxylate is a versatile and valuable compound in the fields of organic synthesis and pharmaceutical research, with its applications extending to the creation of complex organic molecules and the development of new drug candidates with potential therapeutic benefits.

InChI:InChI=1/C11H13NO3/c13-10-6-12(7-10)11(14)15-8-9-4-2-1-3-5-9/h1-5,10,13H,6-8H2

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 45347-82-8 azetidine-3-ol 
• 18621-18-6 azetion-3-ol hydrochloride 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 105258-93-3 N-(Benzyloxycarbonyl)azetidin-3-one 
• 1350607-25-8 benzyl 3-(3-chloropyrazin-2-yloxy)azetidine-1-carboxylate 
• 1093185-36-4 3-oxiranylmethoxyazetidine-1-carboxylic acid benzyl ester 
• 934666-11-2 phenylmethyl 3-[2-(1,3-dioxolan-2-yl)ethylidene]azetidine-1-carboxylate 
• 128117-25-9 methyl 2-Benzyl-3-(1-benzyloxycarbonyl-azetidin-3-ylsulfonyl)propionate 
• 128117-24-8 methyl 2-benzyl-3-<<1-(benzyloxycarbonyl)azetidin-3-yl>thio>propionate 
• 128117-23-7 3-(acetylthio)-1-(benzyloxycarbonyl)azetidine 
• 958297-41-1 tert-butyl 3-((bis(benzyloxy)phosphoryl)oxy)azetidine-1-carboxylate 

Relevant academic research and scientific papers

Fluorescence Assisted Capillary Electrophoresis of Glycans Enabled by the Negatively Charged Auxochromes in 1-Aminopyrenes

A compact and negatively charged acceptor group, N-(cyanamino)sulfonyl, is introduced for dye design and its influence on the absorption and emission spectra of the “push–pull” chromophores is demonstrated with 1,3,6-tris[(cyanamino)sulfonyl]-8-aminopyrene. The new sulfonamides, including O-phosphorylated (3-hydroxyazetidine)-N-sulfonyl, are negatively charged electron acceptors and auxochromes. 1-Aminopyrenes decorated with the new sulfonamides have three or six negative charges (pH ≥8), low m/z ratios, high mobilities in an electric field, and yellow to orange emission. We labeled maltodextrin oligomers by reductive amination, separated the products by electrophoresis, and demonstrated their high brightness in a commercial DNA analyzer and the distribution of the emission signal among the detection channels.

SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES

Provided is a compound of Formula (I): wherein the variable groups are defined herein.

MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

BENZOTHIOPHENE DERIVATIVE

[Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

ACC INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Chiral proton catalysis of secondary nitroalkane additions to azomethine: Synthesis of a potent GlyT1 inhibitor

The first enantioselective synthesis of a potent GlyT1 inhibitor is described. A 3-nitroazetidine donor is used in an enantioselective aza-Henry reaction catalyzed by a bis(amidine)-triflic acid salt organocatalyst, delivering the key intermediate with 92% ee. This adduct is reductively denitrated and converted to the target through a short sequence, thereby allowing assignment of the absolute configuration of the more potent enantiomer.